Lead Product(s) : Nafamostat
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : AcelRx Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Details : The agreement to acquire Lowell will also include LTX-608, Lowell's proprietary nafamostat formulation for direct IV infusion being developed for the treatment of acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC)...
Brand Name : LTX-608
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 15, 2021
Lead Product(s) : Nafamostat
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : AcelRx Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Premier
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Researchers found that patients on a prophylactic dose of the anticoagulants enoxaparin or heparin have shorter hospital stays, lower cost, and better clinical outcomes in Covid-19 patient.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 15, 2021
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Premier
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Monoclonal-bispecific Antibody-based Therapeutics
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Novo Nordisk
Deal Size : $55.0 million
Deal Type : Series A Financing
Novo US$ 55M Series A Generation Therapeutics for BleedingThrombosis Disorders
Details : Proceeds from the financing will be used to progress the Company's promising pipeline of monoclonal and bispecific antibody-based therapeutics into later stages of development.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 22, 2021
Lead Product(s) : Monoclonal-bispecific Antibody-based Therapeutics
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Novo Nordisk
Deal Size : $55.0 million
Deal Type : Series A Financing
Lead Product(s) : FTH1
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : SRS Life Sciences Pte ltd
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement provides SRS exclusive rights for sales, marketing, and distribution of Sidero’s patented biologic iron, BioFeTM, for the management of iron deficiency and related disorders in India and Southeast Asia.
Brand Name : BioFe
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 13, 2020
Lead Product(s) : FTH1
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : SRS Life Sciences Pte ltd
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : VMX-COO1
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Ysios Capital
Deal Size : $36.6 million
Deal Type : Series B Financing
Details : Proceeds to be used to achieve clinical proof of concept for lead compound, VMX-COO1, advance program to registrational studies, accelerate manufacturing trajectory towards commercial scale, and advance the discovery platform program.
Brand Name : VMX-COO1
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 08, 2020
Lead Product(s) : VMX-COO1
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Ysios Capital
Deal Size : $36.6 million
Deal Type : Series B Financing
Lead Product(s) : Abelacimab
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Anthos Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lonza Partners with Anthos Therapeutics for Thrombosis Treatment
Details : The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 11, 2020
Lead Product(s) : Abelacimab
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Anthos Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Hematopoietic stem cells
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Baize Plan Fund
Deal Size : $3.6 million
Deal Type : Collaboration
Details : Through the project, sponsored by the Baize Plan Fund, the Ying laboratory aims to develop conditions for the long-term ex vivo expansion of mouse and human hematopoietic stem and progenitor cells.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 28, 2020
Lead Product(s) : Hematopoietic stem cells
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Baize Plan Fund
Deal Size : $3.6 million
Deal Type : Collaboration
Lead Product(s) : Heparin Sodium
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Cerus DMCC
Deal Size : Undisclosed
Deal Type : Acquisition
CERUS Announces the Acquisition of Laboratori Derivati Organici SpA (LDO) by Opocrin SpA
Details : Transaction enables Opocrin to become a leading global producer of active biologics including heparin and heparinoids.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 29, 2020
Lead Product(s) : Heparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Cerus DMCC
Deal Size : Undisclosed
Deal Type : Acquisition